NCD38, a tranylcypromine-based LSD1 inhibitor that impairs growth of the MLL-AF9-positive leukemia cell model MOLM14, reduces HOXA9 expression and induces myeloid differentiation [192]. Here, HOXA9 is linked to leukemia.